Volume 6.48 | Dec 18

Prostate Cell News 6.48 December 18, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion
Treatment of highly invasive breast and prostate cancer cells with WASF helix mimics inhibitor peptides significantly reduced motility and invasion in vitro. Mechanistic investigations revealed that these inhibitors suppressed the interaction between Rac and the WASF3 complex, which has been shown to promote cell migration. [Cancer Res] Abstract
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Exosomes from Bulk and Stem Cells from Human Prostate Cancer Have a Differential MicroRNA Content that Contributes Cooperatively over Local and Pre-Metastatic Niche
Five prostate cancer primary cell cultures were established to originate bulk and cancer stem cells cultures. From them, exosomes were purified by precipitation for miRNAs extraction to perform a comparative profile of miRNAs by next generation sequencing in an Illumina platform. [Oncotarget] Full Article

Fibroblasts Prolong Serum Prostate-Specific Antigen Decline after Androgen Deprivation Therapy in Prostate Cancer
Scientists investigated the role of fibroblasts in serum prostate-specific antigen decline after androgen deprivation therapy. They performed in vitro experiments using androgen-sensitive, androgen receptor-positive prostate epithelial cell lines, commercially available prostate stromal cells, and primary cultures of prostate fibroblasts. [Lab Invest] Abstract

Exosomal Particles Secreted by Prostate Cancer Cells Are Potent mRNA and Protein Vehicles for the Interference of Tumor and Tumor Environment
Researchers characterized the mRNA and protein composition as well as cellular functions of prostate cancer cell-derived exosomes. Exosomes were prepared from prostate cancer cell culture supernatant by ultracentrifugation and subsequently characterized by dynamic light scattering and electron microscopy. [Prostate] Abstract

Oxidative Stress Resistance in Metastatic Prostate Cancer: Renewal by Self-Eating
Investigators explored resistance mechanisms in the advanced type of prostate cancer cells and aimed to clarify the role of autophagy in these processes. [PLoS One] Full Article

Malformin A1 Promotes Cell Death through Induction of Apoptosis, Necrosis and Autophagy in Prostate Cancer Cells
Investigators reported the mode of mechanism underlying malformin A1-mediated cytotoxicity through induction of apoptosis, necrosis and autophagy in prostate cancer cells. [Cancer Chemother Pharmacol] Abstract

Knockdown of GPR137,G Protein-Coupled Receptor 137, Inhibits the Proliferation and Migration of Human Prostate Cancer Cells
To see whether GPR137 could serve as a potential therapeutic target for prostate cancer (CaP), GPR137 was knocked down to verify its biological function in CaP cells. The authors found that silencing of the GPR137 gene suppressed the proliferation and colony formation of CaP cell lines PC-3 and DU145. [Chem Biol Drug Des] Abstract

Quercetin Inhibits Angiogenesis through Thrombospondin-1 Upregulation to Antagonize Human Prostate Cancer PC-3 Cell Growth In Vitro and In Vivo
The authors explored the important role of thrombospondin-1 upregulation in reducing angiogenesis and anti-prostate cancer effect of quercetin both in vitro and in vivo for the first time. [Oncol Rep] Abstract

CLINICAL RESEARCH

Long-Term Outcome of a Phase II Trial Using Immunomodulatory In Situ Gene Therapy in Combination with Intensity-Modulated Radiotherapy with or without Hormonal Therapy in the Treatment of Prostate Cancer
Investigators report the long-term outcome of a Phase II trial of immune-modulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy for the treatment of prostate cancer. [J Radiat Oncol] Abstract | Press Release

View Webinar: Genome Editing: From Modeling Disease to Novel Therapeutics
 
REVIEWS
Androgen–Glucocorticoid Interactions in the Era of Novel Prostate Cancer Therapy
Great strides have been made in the treatment of castration-resistant prostate cancer with the development of new antiandrogens and more potent androgen synthesis inhibitors that have both improved patient outcomes. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Prostate Cancer Foundation Launches First Competition for Stupski Prize in Prostate Cancer Computational Oncology
The Prostate Cancer Foundation announced the launch of the Stupski Prize Challenge 1. An image analysis data science challenge with a focus on large-scale cancer genomics, this crowdsourced competition aims to rapidly advance precision medicine for advanced prostate cancer patients and extend solutions to other cancers. [The Prostate Cancer Foundation] Press Release

Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Regen BioPharma, Inc. announced identification of a series of compounds that have been identified by biochemical testing which interact with the company’s newly identified immune checkpoint NR2F6. Previously, the company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign. [Regen BioPharma, Inc. (PR Newswire Association LLC)] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine.
Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cancer as an Evolving and Systemic Disease
March 12-15, 2016
New York City, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Bioinformatics (Princess Margaret Cancer Centre)

NEW Professorship – Oncogenic Pathways (German Cancer Research Center)

NEW Professor Position – Cancer Immunotherapy (City of Hope)

PhD Student – Cancer Research (German Cancer Research Center)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Molecular Cancer Biology (University of Pennsylvania)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us